Cells as Vehicles for Cancer Gene Therapy: The Missing Link Between Targeted Vectors and Systemic Delivery?
- 20 July 2002
- journal article
- review article
- Published by Mary Ann Liebert Inc in Human Gene Therapy
- Vol. 13 (11), 1263-1280
- https://doi.org/10.1089/104303402760128504
Abstract
Systemic administration of currently manufactured viral stocks has not so far achieved sufficient circulating titers to allow therapeutic targeting of metastatic disease. This is due to low initial viral titers, immune inactivation, nonspecific adhesion, and loss of particles. One way to exploit the elegant molecular manipulations that have been made to increase vector targeting is to protect these vectors until they reach the local sites of tumor growth. Various cell types home preferentially to tumors and can be loaded with the constructs required to produce targeted vectors. Here we discuss the potential of using such cell carriers to chaperone precious vectors directly to the tumors. The vectors can incorporate mechanisms to achieve tumor site-inducible expression, along with tumor cell-specific expression of the therapeutic gene and/or replicating viral genomes that would be released at the tumor. In this way, the great advances that have so far been made with the engineering of vector tropisms might be genuinely exploited and converted into clinical benefit.Keywords
This publication has 139 references indexed in Scilit:
- Generation of high-titer retroviral vector-producing macrophages as vehicles for in vivo gene transferGene Therapy, 2001
- Regulation of Protein Secretion Through Controlled Aggregation in the Endoplasmic ReticulumScience, 2000
- Genetically modified CD34+ cells as cellular vehicles for gene delivery into areas of angiogenesis in a rhesus modelGene Therapy, 2000
- Angiogenesis and vasculogenesis as therapeutic strategies for postnatal neovascularizationJCI Insight, 1999
- Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo.The Journal of Experimental Medicine, 1996
- Replicating vectors for gene therapy of cancer: risks, limitations and prospectsEuropean Journal Of Cancer, 1994
- T Cell Recognition of Human Tumors: Implications for Molecular Immunotherapy of CancerClinical Immunology and Immunopathology, 1993
- Use of Tumor-Infiltrating Lymphocytes and Interleukin-2 in the Immunotherapy of Patients with Metastatic MelanomaNew England Journal of Medicine, 1988
- A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 AloneNew England Journal of Medicine, 1987
- Clostridial oncolysis in manEuropean Journal of Cancer (1965), 1967